Neurotrophic Keratopathy Market to Expand Significantly by 2032, States DelveInsight Report | ReGenTree, LLC, Oyster Point Pharma, Inc., Dompé Farmaceutici, Syneos Health

DelveInsight's "Neurotrophic Keratopathy Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Neurotrophic Keratopathy, historical and forecasted epidemiology as well as the Neurotrophic Keratopathy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Neurotrophic Keratopathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Neurotrophic Keratopathy Market Forecast
https://www.delveinsight.com/sample-request/neurotrophic-keratopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Neurotrophic Keratopathy Market Report:
• The Neurotrophic Keratopathy market size was valued approximately USD 350 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In April 2025, OKYO Pharma confirmed that urcosimod, previously known as OK-101, maintains stability for over two and a half years in single-use ampoules designed for patient use. This achievement marks a significant advancement in supporting the drug's long-term potential as it moves through clinical development. Urcosimod is currently undergoing a Phase 2b clinical trial-a randomized, placebo-controlled, double-masked study with 48 participants-aimed at evaluating its efficacy in treating neurotrophic keratopathy (NCP), a severe and progressive degenerative eye condition.
• In the 7MM, there were over 138,000 NK cases overall in 2022. It is anticipated that the number of Neurotrophic Keratopathy cases in the 7MM will rise between 2023 and 2032, the prediction period.
• In 2022, out of the seven largest markets, the EU4 and the UK accounted for around 43% of the instances of Neurotrophic Keratopathy
• In the 7MM, there were around 102,000 individuals with Neurotrophic Keratopathy diagnosis overall in 2022. These cases are anticipated to rise as new medicines are approved and awareness is increased.
• The US achieved its greatest prevalence and diagnosed population of Neurotrophic Keratopathy in the 7MM in 2022.
• Key Neurotrophic Keratopathy Companies: ReGenTree, LLC, Oyster Point Pharma, Inc., Dompé Farmaceutici, Syneos Health, Recordati Rare Diseases, MimeTech, Claris Biotherapeutics, and others
• Key Neurotrophic Keratopathy Therapies: RGN-259, OC-01 (varenicline), cenegermin-bkbj, Udonitrectag, rhNGF, REC 0559, CSB-001, and others
• The Neurotrophic Keratopathy epidemiology based on gender analyzed that most of the Neurotrophic Keratopathy cases comprise of the female population
• The Neurotrophic Keratopathy market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Neurotrophic Keratopathy pipeline products will significantly revolutionize the Neurotrophic Keratopathy market dynamics.

Neurotrophic Keratopathy Overview
The rare degenerative corneal disease known as Neurotrophic Keratopathy (NK), also referred to as Neurotrophic Keratitis, is characterized by symptoms such as diminished or absent corneal feeling, impaired healing, and corneal epithelial breakdown, which increases the corneal surface's vulnerability to damage and compromised healing.

Get a Free sample for the Neurotrophic Keratopathy Market Report
https://www.delveinsight.com/report-store/neurotrophic-keratopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Neurotrophic Keratopathy Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Neurotrophic Keratopathy Epidemiology Segmentation:
The Neurotrophic Keratopathy market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Neurotrophic Keratopathy
• Prevalent Cases of Neurotrophic Keratopathy by severity
• Gender-specific Prevalence of Neurotrophic Keratopathy
• Diagnosed Cases of Episodic and Chronic Neurotrophic Keratopathy

Download the report to understand which factors are driving Neurotrophic Keratopathy epidemiology trends @ Neurotrophic Keratopathy Epidemiology Forecast
https://www.delveinsight.com/sample-request/neurotrophic-keratopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Neurotrophic Keratopathy Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Neurotrophic Keratopathy market or expected to get launched during the study period. The analysis covers Neurotrophic Keratopathy market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Neurotrophic Keratopathy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Neurotrophic Keratopathy Therapies and Key Companies
• RGN-259: ReGenTree, LLC
• OC-01 (varenicline): Oyster Point Pharma, Inc.
• cenegermin-bkbj: Dompé Farmaceutici
• Udonitrectag: Syneos Health
• rhNGF: Dompé Farmaceutici
• REC 0559: Recordati Rare Diseases/MimeTech
• CSB-001: Claris Biotherapeutics

Discover more about therapies set to grab major Neurotrophic Keratopathy market share @ Neurotrophic Keratopathy Treatment Market
https://www.delveinsight.com/sample-request/neurotrophic-keratopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Neurotrophic Keratopathy Market Strengths
• Increasing prevalence of other conditions causes neurotrophic Keratopathy, thereby increasing NK population.
• The development of novel molecules potentially targets epithelial healing and corneal innervation
• Advances in biotechnology, laser and robotic treatment also aid in the treatment of Neurotrophic Keratopathy.

Neurotrophic Keratopathy Market Opportunities
• The recent approval of Oxervate by EMA and priority review designation approved by the USFDA will popularize the utilization of recombinant human nerve growth factors for the treatment of neurotrophic Keratopathy during the forecast period.
• Researchers are increasing their investments to develop and discover drugs that could potentially treat rare eye disease

Scope of the Neurotrophic Keratopathy Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Neurotrophic Keratopathy Companies: ReGenTree, LLC, Oyster Point Pharma, Inc., Dompé Farmaceutici, Syneos Health, Recordati Rare Diseases, MimeTech, Claris Biotherapeutics, and others
• Key Neurotrophic Keratopathy Therapies: RGN-259, OC-01 (varenicline), cenegermin-bkbj, Udonitrectag, rhNGF, REC 0559, CSB-001, and others
• Neurotrophic Keratopathy Therapeutic Assessment: Neurotrophic Keratopathy current marketed and Neurotrophic Keratopathy emerging therapies
• Neurotrophic Keratopathy Market Dynamics: Neurotrophic Keratopathy market drivers and Neurotrophic Keratopathy market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Neurotrophic Keratopathy Unmet Needs, KOL's views, Analyst's views, Neurotrophic Keratopathy Market Access and Reimbursement

To know more about Neurotrophic Keratopathy companies working in the treatment market, visit @ Neurotrophic Keratopathy Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/neurotrophic-keratopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Neurotrophic Keratopathy Market Report Introduction
2. Executive Summary for Neurotrophic Keratopathy
3. SWOT analysis of Neurotrophic Keratopathy
4. Neurotrophic Keratopathy Patient Share (%) Overview at a Glance
5. Neurotrophic Keratopathy Market Overview at a Glance
6. Neurotrophic Keratopathy Disease Background and Overview
7. Neurotrophic Keratopathy Epidemiology and Patient Population
8. Country-Specific Patient Population of Neurotrophic Keratopathy
9. Neurotrophic Keratopathy Current Treatment and Medical Practices
10. Neurotrophic Keratopathy Unmet Needs
11. Neurotrophic Keratopathy Emerging Therapies
12. Neurotrophic Keratopathy Market Outlook
13. Country-Wise Neurotrophic Keratopathy Market Analysis (2019-2032)
14. Neurotrophic Keratopathy Market Access and Reimbursement of Therapies
15. Neurotrophic Keratopathy Market Drivers
16. Neurotrophic Keratopathy Market Barriers
17. Neurotrophic Keratopathy Appendix
18. Neurotrophic Keratopathy Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:

Neurotrophic Keratopathy Pipeline https://www.delveinsight.com/report-store/neurotrophic-keratopathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Neurotrophic Keratopathy Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Neurotrophic Keratopathy market. A detailed picture of the Neurotrophic Keratopathy pipeline landscape is provided, which includes the disease overview and Neurotrophic Keratopathy treatment guidelines.

Neurotrophic Keratopathy Epidemiology https://www.delveinsight.com/report-store/neurotrophic-keratopathy-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Neurotrophic Keratopathy Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Neurotrophic Keratopathy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports by DelveInsight
• Post Menopausal Osteoporosis Market: https://www.delveinsight.com/report-store/post-menopausal-osteoporosis-pipeline-insight
• HiPost Menopausal Osteoporosis Market: https://www.delveinsight.com/report-store/post-menopausal-osteoporosis-pipeline-insight
• Hip Replacement Devices Market: https://www.delveinsight.com/report-store/hip-reconstruction-devices-market
• Amblyopia Market: https://www.delveinsight.com/report-store/amblyopia-market
• Type 2 Diabetes Market: https://www.delveinsight.com/report-store/diabetes-market
• Parp Poly Adp-ribose Polymerase Inhibitor Market: https://www.delveinsight.com/report-store/poly-adp-ribose-polymerase-1-parp-inhibitor-pipeline-insight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.